2 ms·
The problem is that we don't have any reliable means to predict in vivo efficacy. Recognizing failed attempts earlier means substantial reductions to the cost
by jcranmer 8y ago
The problem is that we don't have any reliable means to predict in vivo efficacy.
Recognizing failed attempts earlier means substantial reductions to the cost of drugs (i.e., cost savings on the order of hundreds of millions of dollars), so there is very strong financial incentive to stop projects that will fail phase 3 as early as possible. Pretty much every pharmaceutical company has as its "what we'll start doing better" goal as killing off failures earlier. That nothing has appreciably changed in this regard suggests that the fix is beyond our current capabilities--human biology is simply too complicated and too confusing for us to reliably predict at this point.